Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers
View/ Open
File version
Accepted Manuscript (AM)
Author(s)
Russo, S
Walker, JL
Carlson, JW
Carter, J
Ward, LC
Covens, A
Tanner, EJ
Armer, JM
Ridner, S
Hayes, S
Taghian, AG
Brunelle, C
Lopez-Acevedo, M
Davidson, BA
et al.
Griffith University Author(s)
Year published
2021
Metadata
Show full item recordAbstract
Practice changing standardization of lower extremity lymphedema quantitative measurements with integrated patient reported outcomes will likely refine and redefine the optimal risk-reduction strategies to diminish the devastating limb-related dysfunction and morbidity associated with treatment of gynecologic cancers. The National Cancer Institute (NCI), Division of Cancer Prevention brought together a diverse group of cancer treatment, therapy and patient reported outcomes experts to discuss the current state-of-the-science in lymphedema evaluation with the potential goal of incorporating new strategies for optimal evaluation ...
View more >Practice changing standardization of lower extremity lymphedema quantitative measurements with integrated patient reported outcomes will likely refine and redefine the optimal risk-reduction strategies to diminish the devastating limb-related dysfunction and morbidity associated with treatment of gynecologic cancers. The National Cancer Institute (NCI), Division of Cancer Prevention brought together a diverse group of cancer treatment, therapy and patient reported outcomes experts to discuss the current state-of-the-science in lymphedema evaluation with the potential goal of incorporating new strategies for optimal evaluation of lymphedema in future developing gynecologic clinical trials.
View less >
View more >Practice changing standardization of lower extremity lymphedema quantitative measurements with integrated patient reported outcomes will likely refine and redefine the optimal risk-reduction strategies to diminish the devastating limb-related dysfunction and morbidity associated with treatment of gynecologic cancers. The National Cancer Institute (NCI), Division of Cancer Prevention brought together a diverse group of cancer treatment, therapy and patient reported outcomes experts to discuss the current state-of-the-science in lymphedema evaluation with the potential goal of incorporating new strategies for optimal evaluation of lymphedema in future developing gynecologic clinical trials.
View less >
Journal Title
Gynecologic Oncology
Volume
160
Issue
2
Copyright Statement
© 2021 Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
Subject
Oncology and carcinogenesis not elsewhere classified
Allied health and rehabilitation science not elsewhere classified
Clinical sciences
Oncology and carcinogenesis
Reproductive medicine
Gynecologic cancers
Lymphedema
Oncologic surgical treatment
Patient reported outcomes
Quantitative measurements